Aumolertinib as Neoadjuvant and Adjuvant Therapy for Unresectable Stage IIIA-IVA Non-Small Cell Lung Cancer with EGFR Mutations

Due to its low surgical resection rate, stage III lung cancer lacks a standard treatment, and patients with stage IV lung cancer are typically not suitable for surgery. Neoadjuvant EGFR tyrosine kinase inhibitors (TKIs) may improve outcomes, in part by enabling surgery. Aumolertinib is a promising, novel, third-generation EGFR-TKI that has demonstrated excellent efficacy and safety in treating EGFR-mutant non-small-cell lung cancer (NSCLC). However, the clinical benefit of neoadjuvant aumolertinib for EGFR-mutant NSCLC remains unknown.